跳至主要内容
临床试验/NCT02618317
NCT02618317已完成4 期

Comparison of Effectiveness and Safety of Three Lock Solutions for Long-Term Central Venous Catheter for Hemodialysis

University of Sao Paulo1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2013年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
75
试验地点
1
主要终点
Poor Blood Flow Rate(BFR)

研究概览

简要总结

Background: Poor flow (PF) and catheter-related blood stream infections (CRBSI) are highly prevalent among CKD 5D patients with long-term central venous catheters. Heparin (H) catheter lock solutions are commonly used to maintain catheter patency, however PF and CRBSI incidence remains high. The purpose of this study was to evaluate two lock solutions on reduction of PF and CRBSI: one, a lock solution combining of the tetracycline antibiotic minocycline with the anticoagulant/chelation agent EDTA (M-EDTA) versus H; and other, trisodium citrate (C) versus H. M-EDTA and C were also evaluated as to their safety versus H.

Methods:As regards the pilot project, thirty CKD 5D patients on high-efficiency hemodialysis (blood flow rate = 350 ml/min) at the Integrated Centre of Nephrology (Guarulhos, Brazil) were randomized 1:1:1 to receive M-EDTA, C or H locks for 15 weeks. Lock solutions concentrations were M-EDTA 30 mg/ml/3 mg/ml, C 30% (C) and H 1,000 U/ml and both investigators and patients were blinded to treatment allocation. The primary end-point was a 10% reduction in HD blood flow rates (35ml). The frequency of CRBSI was recorded. Bleeding and lock solution-related adverse events were the primary safety end points. Logistic Regression was performed to evaluate differences in PF rates among the treatments (SPSS version 13.0, IBM, USA).

Based upon the pilot-study data, the clinical trials has being executed in order to verify whether the three lock solutions have the same performance or not.

详细描述

Methods: 75 CKD 5D patients on high-efficiency hemodialysis (blood flow rate = 350 ml/min) at the Integrated Centre of Nephrology (Guarulhos, Brazil) will be randomized 1:1:1 to receive M-EDTA, C or H locks for 15 weeks. Lock solutions concentrations are M-EDTA 30 mg/ml/3 mg/ml, C 30% (C) and H 1,000 U/ml and both investigators and patients are blinded to treatment allocation. The primary end-point is a 10% reduction in HD blood flow rates (35ml). The frequency of CRBSI will be recorded. Poor Flow Rate (event/1,000 catheter-day) and CRBSI Rate (event/1,000 catheter-day) will be calculated in each arm. Bleeding and lock solution-related adverse events are also the primary safety end points and their rates (events/1,000 catheter-day) will be calculated. Logistic Regression will be performed to evaluate differences in PF, CRBSI, Bleeding and lock solution-related adverse events rates among the treatments (SPSS version 13.0, IBM, USA).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • male and female patients;
  • patients with subclavian long term central venous catheter;
  • patients on on high-efficiency hemodialysis (BFR= 350 ml; dialisate flow = 500 ml; 3 times; 4-hour sessions).

排除标准

  • pregnant; patients on oral coagulants; patients aged less than 18 years;
  • patients aged more than 75 years

研究组 & 干预措施

Heparin Lock Solution

Active Comparator

Patients on Heparin 1,000 U/ml locking solution, administered at the end of each dialysis session during a 15-week period .

干预措施: Heparin Lock Solution (Drug)

Trissodium Citrate 30%

Experimental

Patients on trissodium citrate 30% locking solution, administered at the end of each dialysis session during a 15-week period .

干预措施: Trissodium Citrate 30% (Drug)

Minocycline-EDTA 30 mg/ml - 3 mg/ml

Experimental

Patients on Minocycline 30 mg/ml/EDTA 3 mg/ml locking solution, administered at the end of each dialysis session during a 15-week period.

干预措施: Minocycline-EDTA 30 mg/ml - 3 mg/ml (Drug)

结局指标

主要结局

Poor Blood Flow Rate(BFR)

时间窗: 100 days

Reduction of 35 ml in the BFR of 2350 ml on hemodialysis is considered a primary endpoint for this trial

次要结局

  • Cather-Related Blood Stream Infection (CRBSI)(100 days)
  • Adverse Drug Reactions Related to lock solutions (ADR)(100 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Marcus Vinicius de Souza Joao Luiz

MSc., Pharm.D.

University of Sao Paulo

研究点 (1)

Loading locations...

相似试验